Investing.com - Genmab (NASDAQ:GMAB) AS reported on Wednesday second quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Genmab AS announced earnings per share of kr0.3938 on revenue of kr434.43M. Analysts polled by Investing.com anticipated EPS of kr0.1954 on revenue of kr411.91M.
Genmab AS shares are down 1% from the beginning of the year, still down 27.27% from its 52 week high of kr49.07 set on September 2, 2021. They are outperforming the STOXX 600 which is down 9.82% from the start of the year.
Genmab AS follows other major Healthcare sector earnings this month
Genmab AS's report follows an earnings beat by UnitedHealth on July 15, who reported EPS of kr5.57 on revenue of kr80.33B, compared to forecasts EPS of kr5.21 on revenue of kr79.68B.
J&J had beat expectations on July 19 with second quarter EPS of kr2.59 on revenue of kr24.02B, compared to forecast for EPS of kr2.54 on revenue of kr23.77B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar